629
Participants
Start Date
March 31, 2008
Primary Completion Date
January 31, 2011
Study Completion Date
July 31, 2012
Entecavir
Tablets, Oral, 1mg, once daily, 100 weeks
Tenofovir
Tablets, Oral, 300 mg, once daily
Adefovir
Tablets, Oral, 10mg, once daily, 100 weeks
Lamivudine
Tablets, Oral, 100mg, once daily, 100 weeks
Local Institution, Taipei
Local Institution, Taoyuan District
Local Institution, Manila
Local Institution, Randwick
Local Institution, Concord
Local Institution, Cebu City
Local Institution, Jakarta
Local Institution, Bangkok
Local Institution, Athens
Local Institution, Bornova Izmir
Local Institution, Antella, Firenze
Local Institution, Chiang Mai
Local Institution, Kuala Lumpur
Local Institution, Tainan R.o.c.
Local Institution, Kaohsiung City
Local Institution, Kota Kinabalu
Local Institution, Porto Alegre Rs
Local Institution, Moscow
Local Institution, New Delhi
Local Institution, Moscow
Local Institution, Singapore
Local Institution, Ludhiana
Local Institution, Chandigarh
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Lucknow
Local Institution, Ahmedabad
Local Institution, Bucheon-si
Local Institution, Indore
Local Institution, Trabzon
Local Institution, Yangsan
Local Institution, Vellore
University Of Connecticut Health Center, Farmington
Local Institution, Calgary
Local Institution, Hong Kong
Local Institution, Shatin
Local Institution, Tai Po
Local Institution, Chorzów
Local Institution, Kielce
Local Institution, Lodz
Local Institution, Lublin
Local Institution, Warsaw
Local Institution, Seoul
Local Institution, Ulsan
Local Institution, Ansan-si
Local Institution, Anyang-si
Local Institution, Seongnam-si
Local Institution, Suwon
Local Institution, Koyang
Local Institution, Incheon
Local Institution, Seoul
Local Institution, Chuncheon
Local Institution, Daegu
Local Institution, Gangneung
Local Institution, Incheon
Local Institution, Pusan
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Suwon
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY